Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 1,471 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Withdrawn Phase 1 Interventional

Testing the Safety of CB-5339 in Patients With Cancer

NCT04372641
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
p97 Inhibitor CB-5339 Tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Results available

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

NCT03340766
View directory record Official record
Conditions
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
Blinatumomab, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
La Jolla, California • Charleston, South Carolina • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers

NCT06345001
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Solid Tumors
Interventions
BAY3630942, BAY3547922
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 29, 2026, 5:10 PM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

NCT05029336
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Depletion of CD3/CD19 in an autologous stem cell transplant
Biological
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
8 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 1 Interventional

Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

NCT03471611
View directory record Official record
Conditions
Atherosclerosis, Coronary
Interventions
Autologous CD34+ Cells, Granulocyte Colony-Stimulating Factor (G-CSF)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 29, 2026, 5:10 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders

NCT02572973
View directory record Official record
Conditions
Separation Anxiety Disorder, Generalized Anxiety Disorder, Social Phobia
Interventions
Acoustic Neuromodulation (ANM)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
7 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 29, 2026, 5:10 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

OBPM_PANDA2026: Evaluation of the Performance and Safety of the Aktiia Periodic Optical Blood Pressure Monitoring Device

NCT07507903
View directory record Official record
Conditions
Hypertension
Interventions
Device under test evaluation against references
Device
Lead sponsor
Aktiia SA
Industry
Eligibility
22 Years to 59 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Broomfield, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 2 Interventional

A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

NCT05238675
View directory record Official record
Conditions
Bronchiectasis
Interventions
BI 1291583, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 85 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Peoria, Arizona • Newport Beach, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

NCT01081223
View directory record Official record
Conditions
Glioma, High Grade Astrocytoma, Glioblastoma Multiforme
Interventions
Cancer vaccine plus immune adjuvant
Biological
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Combining Modafinil and Nicotine Replacement Therapy in Treating Nicotine Dependent Adolescents

NCT00258479
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
ModafinilNicotine Replacement Therapy, Modafinil
Drug
Lead sponsor
Catherine Martin, MD
Other
Eligibility
16 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.

NCT01770314
View directory record Official record
Conditions
Medication Adherence
Interventions
Experimental
Behavioral
Lead sponsor
Inflexxion, Inc.
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®

NCT00920647
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg), Idursulfase IT (30 mg)
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 29, 2026, 5:10 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

Safe Critical Care: Testing Improvement Strategies

NCT00975923
View directory record Official record
Conditions
Central Line-associated Bloodstream Infection (CLABSI), Ventilator Associated Pneumonia
Interventions
Collaborative Group, Tool Kit
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
1 Year and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 29, 2026, 5:10 PM EDT
Terminated Phase 1 Interventional

Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas

NCT00716469
View directory record Official record
Conditions
Neurofibroma
Interventions
LS11
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Perinatal Nurse Home Visiting Enhanced With mHealth Technology

NCT01688427
View directory record Official record
Conditions
Domestic Violence, Intimate Partner Violence
Interventions
Standard IPV Assessment, Standard DOVE Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 29, 2026, 5:10 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Healthy Participants

NCT07701083
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Eloralintide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 5:10 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

NCT04086121
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

NCT01188668
View directory record Official record
Conditions
Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
Interventions
Aripiprazole, Aripiprazole + desvenlafaxine succinate sustained release
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants

NCT04013191
View directory record Official record
Conditions
Elderly Study Participants, Adult Study Participants
Interventions
Padsevonil
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 29, 2026, 5:10 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Work-Related Effects of Heat, Activity, and Fat in Middle Aged Men

NCT02532725
View directory record Official record
Conditions
Obesity, Gender, Problem of Aging
Interventions
Cardiopulmonary Exercise Stress Test, Climatic-Controlled Cardiopulmonary Exercise Stress Test, Body Composition Evaluation, Pre-Exercise Risk Assessment
Procedure
Lead sponsor
Freeman-Sheldon Research Group, Inc.
Other
Eligibility
35 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1972
U.S. locations
1
States / cities
Buckhannon, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Not applicable Interventional Results available

A Single Arm Pilot Study to Refine a Novel Approach to Exercise Promotion Based on Affect-regulation

NCT04903249
View directory record Official record
Conditions
Breast Cancer
Interventions
Core Exercise Promotion Intervention
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Phase 2 Interventional Results available

Candin Safety & Efficacy Study for the Treatment of Warts

NCT01757392
View directory record Official record
Conditions
Warts, Human Papilloma Virus
Interventions
Candida albicans Skin Test Antigen
Biological
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Fort Smith, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 29, 2026, 5:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair

NCT03206567
View directory record Official record
Conditions
Hair Thinning
Interventions
Nutrafol Supplement capsules, Placebo capsules
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 29, 2026, 5:10 PM EDT